vs
Apellis Pharmaceuticals, Inc.（APLS）与BYLINE BANCORP, INC.（BY）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是BYLINE BANCORP, INC.的1.8倍（$199.9M vs $112.4M），BYLINE BANCORP, INC.净利率更高（33.4% vs -29.5%，领先62.9%），BYLINE BANCORP, INC.同比增速更快（9.0% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Byline Bank是总部位于美国伊利诺伊州芝加哥的银行，为银行控股公司Byline Bancorp, Inc.的核心子公司，同时是全美SBA 7(a)贷款项目的第四大放贷机构，为客户提供专业的银行及融资相关服务。
APLS vs BY — 直观对比
营收规模更大
APLS
是对方的1.8倍
$112.4M
营收增速更快
BY
高出15.0%
-5.9%
净利率更高
BY
高出62.9%
-29.5%
两年增速更快
APLS
近两年复合增速
6.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $112.4M |
| 净利润 | $-59.0M | $37.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 33.4% |
| 营收同比 | -5.9% | 9.0% |
| 净利润同比 | -62.2% | 33.0% |
| 每股收益（稀释后） | $-0.40 | $0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSBY
| Q1 26 | — | $112.4M | ||
| Q4 25 | $199.9M | $117.0M | ||
| Q3 25 | $458.6M | $115.7M | ||
| Q2 25 | $178.5M | $110.5M | ||
| Q1 25 | $166.8M | $103.1M | ||
| Q4 24 | $212.5M | $104.7M | ||
| Q3 24 | $196.8M | $101.8M | ||
| Q2 24 | $199.7M | $99.4M |
净利润APLSBY
| Q1 26 | — | $37.6M | ||
| Q4 25 | $-59.0M | $34.5M | ||
| Q3 25 | $215.7M | $37.2M | ||
| Q2 25 | $-42.2M | $30.1M | ||
| Q1 25 | $-92.2M | $28.2M | ||
| Q4 24 | $-36.4M | $30.3M | ||
| Q3 24 | $-57.4M | $30.3M | ||
| Q2 24 | $-37.7M | $29.7M |
营业利润率APLSBY
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 40.1% | ||
| Q3 25 | 48.7% | 43.1% | ||
| Q2 25 | -18.6% | 35.2% | ||
| Q1 25 | -50.0% | 36.4% | ||
| Q4 24 | -12.3% | 38.6% | ||
| Q3 24 | -24.0% | 39.3% | ||
| Q2 24 | -14.7% | 40.4% |
净利率APLSBY
| Q1 26 | — | 33.4% | ||
| Q4 25 | -29.5% | 34.1% | ||
| Q3 25 | 47.0% | 32.1% | ||
| Q2 25 | -23.6% | 27.2% | ||
| Q1 25 | -55.3% | 27.4% | ||
| Q4 24 | -17.1% | 34.3% | ||
| Q3 24 | -29.2% | 29.8% | ||
| Q2 24 | -18.9% | 29.9% |
每股收益（稀释后）APLSBY
| Q1 26 | — | $0.83 | ||
| Q4 25 | $-0.40 | $0.77 | ||
| Q3 25 | $1.67 | $0.82 | ||
| Q2 25 | $-0.33 | $0.66 | ||
| Q1 25 | $-0.74 | $0.64 | ||
| Q4 24 | $-0.30 | $0.68 | ||
| Q3 24 | $-0.46 | $0.69 | ||
| Q2 24 | $-0.30 | $0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $198.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.3B |
| 总资产 | $1.1B | $9.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSBY
| Q1 26 | — | $198.4M | ||
| Q4 25 | $466.2M | $149.1M | ||
| Q3 25 | $479.2M | $259.0M | ||
| Q2 25 | $370.0M | $218.3M | ||
| Q1 25 | $358.4M | $421.3M | ||
| Q4 24 | $411.3M | $563.1M | ||
| Q3 24 | $396.9M | $452.6M | ||
| Q2 24 | $360.1M | $730.5M |
股东权益APLSBY
| Q1 26 | — | $1.3B | ||
| Q4 25 | $370.1M | $1.3B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.2B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.0B |
总资产APLSBY
| Q1 26 | — | $9.9B | ||
| Q4 25 | $1.1B | $9.7B | ||
| Q3 25 | $1.1B | $9.8B | ||
| Q2 25 | $821.4M | $9.7B | ||
| Q1 25 | $807.3M | $9.6B | ||
| Q4 24 | $885.1M | $9.5B | ||
| Q3 24 | $901.9M | $9.4B | ||
| Q2 24 | $904.5M | $9.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSBY
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $140.3M | ||
| Q3 25 | $108.5M | $38.3M | ||
| Q2 25 | $4.4M | $16.3M | ||
| Q1 25 | $-53.4M | $27.1M | ||
| Q4 24 | $19.4M | $175.2M | ||
| Q3 24 | $34.1M | $19.8M | ||
| Q2 24 | $-8.3M | $40.1M |
自由现金流APLSBY
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $136.3M | ||
| Q3 25 | $108.3M | $38.0M | ||
| Q2 25 | $4.4M | $15.2M | ||
| Q1 25 | $-53.4M | $25.0M | ||
| Q4 24 | $19.3M | $171.2M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | $-8.4M | $39.4M |
自由现金流率APLSBY
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 116.5% | ||
| Q3 25 | 23.6% | 32.8% | ||
| Q2 25 | 2.5% | 13.7% | ||
| Q1 25 | -32.0% | 24.3% | ||
| Q4 24 | 9.1% | 163.5% | ||
| Q3 24 | — | 18.8% | ||
| Q2 24 | -4.2% | 39.7% |
资本支出强度APLSBY
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.4% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 2.0% | ||
| Q4 24 | 0.0% | 3.8% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 0.7% |
现金转化率APLSBY
| Q1 26 | — | — | ||
| Q4 25 | — | 4.06× | ||
| Q3 25 | 0.50× | 1.03× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | 5.78× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BY
暂无分部数据
